Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey

Autor: Mohammed I. Aladul, Stephen J. Chapman, Ray Fitzpatrick
Rok vydání: 2017
Předmět:
Health Knowledge
Attitudes
Practice
knowledge
medicine.medical_specialty
Attitude of Health Personnel
media_common.quotation_subject
Alternative medicine
Dermatology
RS
RC648
03 medical and health sciences
0302 clinical medicine
Rheumatology
Excellence
Surveys and Questionnaires
Pharmacovigilance
medicine
Humans
Hypoglycemic Agents
030212 general & internal medicine
Practice Patterns
Physicians'
Formulary
Biosimilar Pharmaceuticals
media_common
Biosimilars
030203 arthritis & rheumatology
Internet
Drug Substitution
business.industry
Insulin glargine
Research
Gastroenterologists
insulin glargine
Biosimilar
General Medicine
healthcare professionals
R1
Drug Utilization
United Kingdom
Infliximab
attitude
Family medicine
Professional association
Health Services Research
infliximab
business
medicine.drug
Zdroj: BMJ Open
ISSN: 2044-6055
DOI: 10.1136/bmjopen-2017-016730
Popis: Objective To investigate healthcare professionals’ knowledge and attitudes towards infliximab and insulin glargine biosimilars and the factors influencing their prescribing. Then, to compare healthcare professionals’ attitudes with the utilisation of these biosimilars in UK hospitals. Design Self-administered, one-time web-based survey and drug utilisation analysis. Setting and data sources Professional associations and societies in the field of dermatology, diabetology, gastroenterology and rheumatology in the UK, between 8 August 2016 and 8 January 2017. The volume of utilisation of branded and biosimilar infliximab and insulin glargine in UK hospitals was derived from the DEFINE database, between 2015 and 2016. Outcomes Participants’ knowledge and awareness of biosimilars and factors influencing their use and corresponding usage of infliximab and insulin glargine biosimilars. Results Responses were obtained from 234 healthcare professionals across dermatology, diabetology, gastroenterology and rheumatology specialties. 75% of respondents were aware that biosimilars were available on their local formulary. 77% of respondents considered biosimilars extremely or very important to save costs for the NHS. Gastroenterologists had the highest utilisation of infliximab biosimilars (14%) in 2015 rising to (62%) in 2016. Healthcare professionals had greater concerns about safety and efficacy when switching patients to biosimilars than when starting biosimilars in biological naive patients. Guidance from National Institute for Health and Care Excellence and robust pharmacovigilance studies on biosimilars were both considered important factors in increasing biosimilars use. Conclusion British healthcare professionals are well informed about biosimilars with high level of awareness. Safety and efficacy concerns were higher in switching than in initiating biosimilars among some prescribers. It is probable that personal experience of biologics as well as discipline-specific guidance influenced prescribers’ responses.
Databáze: OpenAIRE
Externí odkaz: